Prof Han Chong Toh National Cancer Centre Singapore Singapore

Han Chong Toh is Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore and Professor at the Duke NUS Medical School. Prof Toh obtained his BSc (Intercalated) from the University of London in ‘Infection and Immunity’ and his medical degree from the University of Cambridge, UK. His oncology and translational research training were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas, USA. Prof Toh is alumni of the Harvard Business School General Management Program. He is Principal Lead, Cellular Immunotherapy at the Singhealth Duke NUS Cell Therapy Centre. He is recipient of National Senior Clinician Scientist Award in 2017 and National Medical Excellence Award (NMEA) in 2018 for his pioneering work in cell and immunotherapy for cancer.


Prof Toh leads the NMRC LCG VICTORY (Virus-Induced Cancers Translational Oncology and immunologY) grant and is recipient of the NMRC STaR Award 2022 focusing on the translational understanding and therapeutic development for viral and non-viral hepatocellular carcinoma and is active in HCC and other gastrointestinal cancer clinical research and clinical trials. He co-leads a multi-international phase III clinical trial ASCOLT (Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers) investigating the role of secondary chemoprevention using aspirin in resected colorectal cancer – the world’s first prospective clinical trial investigating adjuvant aspirin as secondary prevention in resected colorectal cancer (n = 1587). This manuscript has been submitted. Prof Toh is European Society for Medical Oncology (ESMO) faculty for Cancer Immunology and on the ESMO Annual Congress 2024 Scientific Committee. He is co-lead of the ESMO Asia 2024 Immunotherapy Educational Session which he will chair. He is also on the Scientific organising committee for APPLE – Asia-Pacific Primary Liver Cancer Expert Meeting 2024 He is co-founder of the Asia-Pacific Gastrointestinal Cancer Summit (APGCS) in its 11th year. He has published over 150 peer review journal papers.